PersonaDx

PersonaDx

医院和医疗保健

Chicago,Illinois 155 位关注者

AI Precision in Metastatic Cancer Care

关于我们

At PersonaDx, we are redefining cancer care by harnessing molecular genetics and clinical risk factors with a clinically validated neural network. Our mission is to advance the predictive and therapeutic landscape in oncology, providing unmatched accuracy in cancer prognosis. We are actively seeking partnerships in various areas, including pharmaceutical companies, research institutions, genomic sequencing labs, and healthcare providers. Join us in our mission to transform cancer therapy and improve patient outcomes worldwide. PersonaDx integrates molecular genetics and clinical data powered by AI to revolutionize cancer prognosis, delivering unmatched accuracy in predicting recurrence and optimizing treatment plans for metastatic tumors. With a clinically validated 96% accuracy rate, PersonaDx sets a new standard in precision medicine. Metastasis-Centric Approach Defines integrated risk groups that are highly prognostic for survival after treatment. Precision-Driven Decisions Accurate, data-driven therapeutic recommendations leveraging genomics and clinical data. Superior Treatment Predictions Informs personalized treatment based on the identified phenotype of the metastasis. Innovative Products - Persona31g & Persona150gz: Advanced subtyping tools with proprietary biomarkers. - PersonaAI: AI-driven platform advising the clinical team throughout the care path. Key Highlights - 96% accuracy of 31-feature neural network. - Enhanced Survival Rates: Significant increases with biomarker-informed predictions. 5-year OS of 30-90% versus current coin flip. - Proven Success: Phase 3 New-EPOC trial shows superior predictive power. - 25% Exceptional Outcomes: Patients achieve excellent survival/cure after treatment. Join us in transforming cancer therapy and improving patient outcomes worldwide. Discover how PersonaDx can transform cancer prognostics and treatment. Contact us to learn more at [email protected].

网站
persona-dx.com
所属行业
医院和医疗保健
规模
2-10 人
总部
Chicago,Illinois
类型
私人持股
创立
2022
领域
Metastatic Cancer、Diagnosis、Radiotherapy、Immunotherapy、Cancer、Biotechnology、Genetic Sequencing、AI-Powered Cancer Prognosis、Cancer Prognosis、Metastatic Cancer Prognosis、Precision Medicine、Personalized Medicine、Personalized Cancer Prognosis、Precision Oncology、Metastatic Tumor、Genomic Sequencing、Precision Oncology Solutions、AI-Driven Cancer Diagnostics、Personalized Metastatic Cancer Prognosis、Advanced Molecular Genetics in Cancer Care、AI-Driven Cancer Diagnostics、High-Accuracy Cancer Prognosis 、Pharmaceutical Partnerships in Oncology、Targeted Cancer Therapy Insights和AI Integration in Cancer Research

地点

  • 主要

    600 W Jackson Blvd

    US,Illinois,Chicago,60661

    获取路线

动态

  • PersonaDx转发了

    查看PersonaDx的公司主页,图片

    155 位关注者

    Congratulations to Ralph Weichselbaum, MD, Founder and Chief Scientific Officer at PersonaDx, on being honored as an inductee of the OncLive 12th Annual Giants of Cancer Care recognition program! Your exceptional contributions to radiation oncology continue to inspire us, and we're proud to have you driving innovation in cancer care.

  • 查看PersonaDx的公司主页,图片

    155 位关注者

    Congratulations to Ralph Weichselbaum, MD, Founder and Chief Scientific Officer at PersonaDx, on being honored as an inductee of the OncLive 12th Annual Giants of Cancer Care recognition program! Your exceptional contributions to radiation oncology continue to inspire us, and we're proud to have you driving innovation in cancer care.

  • 查看PersonaDx的公司主页,图片

    155 位关注者

    ??? ???????? ???????????????? ?????????????? ???????? ????. ???????? ??????????????: ???????????????????????? ???? ???????????????????? ???????????????????? ???????????? ????????????????! ? We are excited to share that Dr. Sean Pitroda, Founder and Chief Medical Officer at PersonaDx, was recently featured on JAMA Oncology's Author Interviews podcast with the esteemed Dr. Jack West. In this episode, Dr. Pitroda discusses the groundbreaking research on the ???????????????????? ????????????????-?????????????????? ???????????????????????????? ???? ???????????????????? ?????????? ????????????????????. This research, conducted at the University of Chicago Medicine Comprehensive Cancer Center and validated through the Phase 3 New EPOC randomized clinical trial, forms the foundation of PersonaDx's precision oncology solutions. The findings from this trial are integral to our biomarker assay, PersonaCRC, which leverages cutting-edge technology to classify metastatic colorectal cancer into specific prognostic molecular subtypes with 96% accuracy. While the current focus is on metastatic colorectal cancer, the innovative framework and neural network-driven approach have the potential to revolutionize the treatment of other types of metastatic cancers in the future. This work not only advances the field of metastatic cancer care but also opens the door for further development of assays tailored to various cancer types. ?? ???????????? ?????? ?????? ?????????????? ?????? ???????????? ???? ?????????????????? ????????????????:?https://lnkd.in/guwnyrg9 ????. ???????? ?????????????? ???? ?? ?????????????? ?????? ?????? ?????????? ?????????????? ?????????????? (??????) ???? ??????????????????. ???? ???????????????? ???? ?????? ???????? ???? ??????????????????, ???? ???? ???????? ???? ?????????????????? ?????????????????? ???? ?????????????????? ?????? ???????????????? ???????????????? ???? ?????? ???????????????????? ???? ?????????????? ?????? ?? ?????????????????? ???????????????????????? ???? ?????? ???????????? ???????????? ?????? ???????????????????? ????????????????. ????. ?????????????? ?????? ???? ?????????????????? ???????????????????? ???? ???????????????? ????????????????, ???????? ???????? 90 ???????????????????????? ?????? ???????????????? ?????????????? ???? ?????? ????????. #PersonaDx #PrecisionOncology #MetastaticColorectalCancer #LiverMetastases #ClinicalResearch #CancerTreatment #HealthcareInnovation

    • 该图片无替代文字
  • 查看PersonaDx的公司主页,图片

    155 位关注者

    Partner with PersonaDx to help change the future of metastatic cancer, responsible for 90% of all cancer deaths as stated by the American Cancer Society. Learn more about their innovative AI-driven solutions, delivering 96% accuracy in prognosis and treatment optimization.

    查看PersonaDx的公司主页,图片

    155 位关注者

    Partner with PersonaDx to Advance Metastatic Cancer Prognosis and Treatment At PersonaDx, we integrate molecular genetics and clinical data powered by AI to set a new standard in cancer prognosis. With a clinically validated 96% accuracy rate, our technology is revolutionizing prognosis and optimization of treatment plans for metastatic tumors. We are seeking strategic partnerships across multiple areas: ?? Pre-Clinical Partnerships: Collaborate with us on early-stage research to further validate enhance your research and validate our diagnostic accuracy across multiple cancer types, including mCRC (metastatic colorectal cancer). ?? Existing Diagnostics Partnerships: Explore opportunities to integrate PersonaDx’s cutting-edge technology with your existing diagnostic platforms, starting with mCRC. ?? mCRC Companion Diagnostic Partnerships: Partner with us to develop and market companion diagnostics to provide greater precision ?in treating patients with mCRC . ?? Genetic Sequencing Partnerships: Combine your genomic sequencing capabilities with our RNA based biomarkers to expand your revenue opportunities while improving outcomes for patient being treated for mCRCand other metastatic cancers. Explore these and other partnership opportunities, by contacting Kevin Donnelly at [email protected]. Follow PersonaDx Stay informed on how we’re revolutionizing cancer care. Follow PersonaDx on LinkedIn https://lnkd.in/g4zuAv-x for the latest updates on our mission to transform metastatic cancer prognostics. #PersonaDx #mCRC #CancerDiagnostics #GenomicMedicine #Partnerships #HealthcareInnovation #PrecisionMedicine

    • 该图片无替代文字
  • 查看PersonaDx的公司主页,图片

    155 位关注者

    Partner with PersonaDx to Advance Metastatic Cancer Prognosis and Treatment At PersonaDx, we integrate molecular genetics and clinical data powered by AI to set a new standard in cancer prognosis. With a clinically validated 96% accuracy rate, our technology is revolutionizing prognosis and optimization of treatment plans for metastatic tumors. We are seeking strategic partnerships across multiple areas: ?? Pre-Clinical Partnerships: Collaborate with us on early-stage research to further validate enhance your research and validate our diagnostic accuracy across multiple cancer types, including mCRC (metastatic colorectal cancer). ?? Existing Diagnostics Partnerships: Explore opportunities to integrate PersonaDx’s cutting-edge technology with your existing diagnostic platforms, starting with mCRC. ?? mCRC Companion Diagnostic Partnerships: Partner with us to develop and market companion diagnostics to provide greater precision ?in treating patients with mCRC . ?? Genetic Sequencing Partnerships: Combine your genomic sequencing capabilities with our RNA based biomarkers to expand your revenue opportunities while improving outcomes for patient being treated for mCRCand other metastatic cancers. Explore these and other partnership opportunities, by contacting Kevin Donnelly at [email protected]. Follow PersonaDx Stay informed on how we’re revolutionizing cancer care. Follow PersonaDx on LinkedIn https://lnkd.in/g4zuAv-x for the latest updates on our mission to transform metastatic cancer prognostics. #PersonaDx #mCRC #CancerDiagnostics #GenomicMedicine #Partnerships #HealthcareInnovation #PrecisionMedicine

    • 该图片无替代文字
  • 查看PersonaDx的公司主页,图片

    155 位关注者

    @ASCO paper from our founders Ralph Weichselbaum and Sean Pitroda #cancer #immunotherapy #ICI #metastasis

相似主页